Basket Trials Evaluating Tazemetostat Combinations for Multiple New Heme and Solid Tumor Cancers to be Initiated in Second Half 2021 “The recent accelerated approvals of TAZVERIK in Epithelioid ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
Genesis has long recognized that the strength of any care delivery system lies not just in infrastructure or technology, but ...
Common early-phase pitfalls, from misaligned nonclinical strategy to gaps in CMC, bioanalysis, and species selection, can delay IND and CTA submissions. By aligning development plans with regulatory ...
Designed to encourage interaction and collaboration, SCOPE X emphasizes detailed case studies, peer-driven discussions, and ...
MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today ...
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the ...
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry Toronto, ...
Orionis Biosciences, a privately held, clinical‑stage life sciences company focused on discovery, design and development of precision medicines for cancer and immune system-related disorders, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results